Department of Psychiatry, University of Pennsylvania, Philadelphia.
Department of Psychology, Southern Methodist University, Dallas, Texas.
JAMA. 2013 Dec 25;310(24):2650-7. doi: 10.1001/jama.2013.282829.
Evidence-based treatments for posttraumatic stress disorder (PTSD) have not been established for adolescents despite high prevalence of PTSD in this population.
To examine the effects of counselor-delivered prolonged exposure therapy compared with supportive counseling for adolescents with PTSD.
DESIGN, SETTING, AND PARTICIPANTS: A single-blind, randomized clinical trial of 61 adolescent girls with PTSD using a permuted block design. Counselors previously naive to prolonged exposure therapy provided the treatments in a community mental health clinic. Data collection lasted from February 2006 through March 2012.
Participants received fourteen 60- to 90-minute sessions of prolonged exposure therapy (n = 31) or supportive counseling (n = 30).
All outcomes were assessed before treatment, at mid-treatment, and after treatment and at 3-, 6-, and 12-month follow-up. The primary outcome, PTSD symptom severity, was assessed by the Child PTSD Symptom Scale-Interview (range, 0-51; higher scores indicate greater severity). Secondary outcomes were presence or absence of PTSD diagnosis assessed by the DSM-IV Schedule for Affective Disorders and Schizophrenia for School-Age Children and functioning assessed by the Children's Global Assessment Scale (range, 1-100; higher scores indicate better functioning). Additional secondary measures, PTSD severity assessed by the Child PTSD Symptom Scale-Self-Report (range, 0-51; higher scores indicate greater severity) and depression severity assessed by the Children's Depression Inventory (range, 0-54; higher scores indicate greater severity), were also assessed weekly during treatment.
Data were analyzed as intent to treat. During treatment, participants receiving prolonged exposure demonstrated greater improvement on the PTSD symptom severity scale (difference between treatments in improvement, 7.5; 95% CI, 2.5-12.5; P < .001) and on all secondary outcomes (loss of PTSD diagnosis: difference, 29.3%, 95% CI, 20.2%-41.2%; P = .01; self-reported PTSD severity: difference, 6.2; 95% CI, 1.2-11.2; P = .02; depression: difference, 4.9; 95% CI, 1.6-8.2; P = .008; global functioning: difference, 10.1; 95% CI, 3.4-16.8; P = .008). These treatment differences were maintained through the 12-month follow-up: for interviewer-assessed PTSD (difference, 6.0; 95% CI, 1.6-10.4; P = .02), loss of PTSD diagnosis (difference, 31.1; 95% CI, 14.7-34.8; P = .01), self-reported PTSD (difference, 9.3; 95% CI, 1.2-16.5; P = .02), depression (difference, 7.2; 95% CI, 1.4-13.0; P = .02), and global functioning (difference, 11.2; 95% CI, 4.5-17.9; P = .01).
Adolescents girls with sexual abuse-related PTSD experienced greater benefit from prolonged exposure therapy than from supportive counseling even when delivered by counselors who typically provide supportive counseling.
clinicaltrials.gov Identifier: NCT00417300.
尽管 PTSD 在该人群中普遍存在,但针对青少年 PTSD 的循证治疗方法尚未确立。
研究咨询师提供的延长暴露疗法与支持性咨询对 PTSD 青少年的疗效比较。
设计、设置和参与者:一项采用随机区组设计的单盲随机临床试验,纳入 61 名患有 PTSD 的青春期女孩。在社区心理健康诊所,之前对延长暴露疗法一无所知的咨询师提供了治疗。数据收集从 2006 年 2 月持续到 2012 年 3 月。
参与者接受了十四次 60-90 分钟的延长暴露治疗(n=31)或支持性咨询(n=30)。
所有结果在治疗前、治疗中期、治疗后以及 3、6 和 12 个月随访时进行评估。主要结局为儿童 PTSD 症状量表访谈(范围 0-51;分数越高表示严重程度越高)评估的 PTSD 症状严重程度。次要结局为 DSM-IV 情感障碍和儿童青少年学校用时间表评估的 PTSD 诊断存在或不存在,以及儿童总体评估量表(范围 1-100;分数越高表示功能越好)评估的功能。其他次要措施,包括儿童 PTSD 症状量表自我报告(范围 0-51;分数越高表示严重程度越高)评估的 PTSD 严重程度和儿童抑郁量表(范围 0-54;分数越高表示严重程度越高)评估的抑郁严重程度,也在治疗期间每周评估。
数据作为意向治疗进行分析。在治疗期间,接受延长暴露治疗的参与者在 PTSD 症状严重程度量表上(治疗组之间改善的差异,7.5;95%CI,2.5-12.5;P<.001)和所有次要结局上(失去 PTSD 诊断:差异,29.3%,95%CI,20.2%-41.2%;P=.01;自我报告的 PTSD 严重程度:差异,6.2;95%CI,1.2-11.2;P=.02;抑郁:差异,4.9;95%CI,1.6-8.2;P=.008;总体功能:差异,10.1;95%CI,3.4-16.8;P=.008)的改善更为显著。这些治疗差异在 12 个月随访时仍保持:访谈评估的 PTSD(差异,6.0;95%CI,1.6-10.4;P=.02)、失去 PTSD 诊断(差异,31.1;95%CI,14.7-34.8;P=.01)、自我报告的 PTSD(差异,9.3;95%CI,1.2-16.5;P=.02)、抑郁(差异,7.2;95%CI,1.4-13.0;P=.02)和总体功能(差异,11.2;95%CI,4.5-17.9;P=.01)。
性虐待相关 PTSD 的青春期女孩从延长暴露疗法中获益多于支持性咨询,即使咨询师通常提供支持性咨询。
clinicaltrials.gov 标识符:NCT00417300。